EGFR and glioblastoma: A phase II study of erlotinib 150 mg daily in 13 recurrent glioblastoma patients that were PTEN positive, EGFR positive, and EGFRvIII positive by immunohistochemistry (IHC) was stopped early for lack of efficacy (results published 2014) [66].